Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 14,600 shares of the firm’s stock in a transaction that occurred on Friday, November 11th. The shares were bought at an average cost of $9.46 per share, for a total transaction of $138,116.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $29,032,276.46. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were acquired at an average price of $9.33 per share, with a total value of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The shares were acquired at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.49 per share, with a total value of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The shares were acquired at an average price of $9.43 per share, with a total value of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.46 per share, with a total value of $94,600.00.
  • On Thursday, October 27th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.36 per share, with a total value of $93,600.00.
  • On Wednesday, October 26th, Phillip Md Et Al Frost bought 5,600 shares of Opko Health stock. The shares were acquired at an average price of $9.27 per share, with a total value of $51,912.00.
  • On Tuesday, October 25th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were acquired at an average price of $9.38 per share, with a total value of $33,768.00.
  • On Monday, October 24th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were acquired at an average price of $9.50 per share, with a total value of $17,100.00.

Opko Health Inc. (NYSE:OPK) opened at 10.23 on Wednesday. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The firm’s market cap is $5.70 billion. The company’s 50-day moving average is $9.81 and its 200 day moving average is $9.85.

Opko Health (NYSE:OPK) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.03) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). The business had revenue of $298 million for the quarter, compared to the consensus estimate of $322 million. During the same quarter last year, the business posted $0.25 EPS. The business’s revenue for the quarter was up 108.4% on a year-over-year basis. On average, equities research analysts predict that Opko Health Inc. will post ($0.07) earnings per share for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

Several institutional investors have recently bought and sold shares of OPK. Credit Suisse AG raised its position in Opko Health by 7.7% in the third quarter. Credit Suisse AG now owns 303,666 shares of the company’s stock valued at $3,216,000 after buying an additional 21,712 shares during the period. Verition Fund Management LLC acquired a new position in Opko Health during the third quarter valued at $196,000. Jane Street Group LLC raised its position in Opko Health by 237.0% in the third quarter. Jane Street Group LLC now owns 333,634 shares of the company’s stock valued at $3,533,000 after buying an additional 234,647 shares during the period. Moors & Cabot Inc. raised its position in Opko Health by 10.0% in the third quarter. Moors & Cabot Inc. now owns 67,186 shares of the company’s stock valued at $712,000 after buying an additional 6,086 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its position in Opko Health by 325.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 111,624 shares of the company’s stock valued at $1,182,000 after buying an additional 85,393 shares during the period.

A number of research firms have recently weighed in on OPK. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. TheStreet lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. Oppenheimer Holdings Inc. reissued a “market perform” rating on shares of Opko Health in a research report on Thursday, August 11th. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $13.17.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.